REGN
Regeneron Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website regeneron.com
- Employees(FY) 12463
- ISIN US75886F1075
Performance
+7.14%
1W
+3.15%
1M
+2.28%
3M
+17.65%
6M
+10.21%
YTD
+28.23%
1Y
Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Investment Analysis Report: Regeneron Pharmaceuticals Inc. (REGN)
Overview:
Regeneron Pharmaceuticals Inc. (REGN) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. With a market capitalization of $105.91 billion, REGN is a significant player in the pharmaceutical industry. This report will provide a d...
Technical Analysis of REGN 2024-05-03
Overview:
In analyzing the technical indicators for REGN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Indicators...
Recent News & Updates
- 2024-05-09 06:51
Regeneron’s gene therapy triumphs twice, restoring hearing in children(Clinical Trials Arena)
- 2024-05-08 07:30
Regeneron gene therapy improves hearing in two children(BioPharma Dive)
- 2024-05-08 06:07
- 2024-05-08 06:00
- 2024-05-07 18:00
- 2024-05-07 10:45
- 2024-05-07 04:05
Regeneron Announces Investor Conference Presentations(Globenewswire)
- 2024-05-06 16:05
Regeneron Announces Investor Conference Presentations(GlobeNewswire)
- 2024-05-05 20:46
Analyst Report: Regeneron Pharmaceuticals, Inc.(Morningstar Research)
- 2024-05-05 00:00
- 2024-05-04 07:38
23 Most Profitable Stocks of the Last 12 Months(Insider Monkey)
- 2024-05-03 19:38
23 Most Profitable Stocks of the Last 12 Months(Insidermonkey)
- 2024-05-03 10:20
- 2024-05-03 10:15
- 2024-05-03 09:56
- 2024-05-03 09:01
- 2024-05-03 03:10
- 2024-05-03 01:08
- 2024-05-02 22:53
- 2024-05-02 22:01
- 2024-05-02 21:30
- 2024-05-02 18:15
- 2024-05-02 14:51
- 2024-05-02 13:54
- 2024-05-02 13:52
- 2024-05-02 11:52
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms(Investor's Business Daily)
- 2024-05-02 10:01
- 2024-05-02 09:30
- 2024-05-02 08:32
- 2024-05-02 08:00
Page 1 of 10
previousnext